Breaking News

Recipharm, Isofol in Modufolin Mfg. Pact

August 26, 2014

Recipharm Venture Fund invests $1.15 million in Isofol

Recipharm and Isofol Medical AB have entered a collaboration for the development and manufacture of Isofol’s lead drug candidate Modufolin, an endogenous folate-based biomodulator currently being evaluated in two Phase I/II studies. Modufolin has the potential to increase the efficacy and decrease the side effects of chemotherapeutic agents used in the treatment of solid tumors.
 
Addionally, Recipharm Venture Fund has invested $1.15 million in Isofol Medical. 
 
Carl-Johan Spak, executive vice president of Development & Technology, Recipharm, said, “We are very pleased to have further developed our collaborative partnership with Isofol Medical and to have now signed an agreement for future exclusive commercial manufacturing of Modufolin, especially as this is a new, innovative drug, focused on tumor treatment and consequently has strong sales potential.”
 
“Given the promising clinical data we have obtained to date we want to secure the long term manufacture and supply of Modufolin® for its future commercialization. With Recipharm’s investment of 8 MSEK in Isofol we have now raised 45 MSEK during the last 8 months. This capital and the collaboration with Recipharm not only strengthens the ongoing Phase II clinical development program but could also secure the future commercialization of Modufolin,” said Anders Rabbe, managing director of Isofol.

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016